A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)

Completed · Phase 1

Conditions studied: Healthy

In brief

The goal of this study is to learn what happens to a single dose of alendronate over time in a healthy participant's body when the participant is given a single dose of enlicitide decanoate. Researchers want to learn how safe and tolerable is the co-administration of enlicitide decanoate and alendronate.

Key facts

Study ID

NCT06772792

Run by

Merck Sharp & Dohme LLC

People needed

36

Starts

2024-04-23

Expected to finish

2024-06-21

Last updated by the study team

2025-02-18

Who can join

Age: 19 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Has no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, and electrocardiograms (ECGs)
• Has a body mass index (BMI) ≥18.0 kg/m\^2 and ≤32.0 kg/m\^2 (inclusive)

You may not qualify if…

• Has a history or presence of abnormalities of the esophagus which delay emptying such as stricture or achalasia
• Has a history of cancer (malignancy)
• Has a history of gastrointestinal disease which may affect food and drug absorption

Where it is running

• Celerion (Site 0001) — Lincoln, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.